MLTX INVESTOR REPORT: BFA Law Alerts MoonLake Immunotherapeutics Investors that a Class Action Lawsuit was Filed Against the Company for Fraud and Urges You to Contact the Firm
BFA Law has filed a class action lawsuit against MoonLake Immunotherapeutics (MLTX) alleging securities fraud and encourages investors to contact them.Summary
Bleichmar Fonti & Auld LLP (BFA) announced a lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives, alleging violations of federal securities laws. The lawsuit claims that MoonLake misled investors regarding the clinical data and structure of its investigational drug, sonelokimab (SLK), for hidradenitis suppurativa (HS). Specifically, the company stated its data showed “higher clinical responses” and a beneficial Nanobody structure compared to competitors, which the suit alleges was untrue. Following the release of disappointing Phase 3 VELA trial results on September 28, 2025, MoonLake’s stock price plummeted nearly 90%, falling from $61.99 to $6.24 per share. Investors who purchased MoonLake common stock are encouraged to contact BFA by December 15, 2025, to potentially join the lawsuit. BFA is a leading securities law firm with a history of successful recoveries, including over $900 million from Tesla and $420 million from Teva Pharmaceutical.
(Source：Newsfile)